Close×

A US brewer has picked up a semi-rigid container from a Queensland company for its new range of craft beer concentrates.

North American packaging company Technical Help in Engineering and Marketing (THEM) promotes the Snapsil technology, which includes a range of creative dispensing designs.

Snapsil's headquarters are in Birtinya, Queensland.

The company's semi-rigid containers feature a patented, audible ‘snap-opening’ function that allows consumers to easily open the package and dispense the contents with one hand.

The snap-opening function is integrated into the lower web of the thermoformed pack, and there is no requirement for any type of perforation of the film in the opening area of the portion pack.

This provides uncompromised barrier properties for package contents.

“It didn’t make sense to put our Foxboro Spirited Brews in a typical, everyday package,” Foxboro co-founder Charn Rai said.

“Our beer concentrate is a unique, disruptive product, so we wanted the packaging to be just as different and special, as well as user-friendly.”

THEM’s facility offers contract manufacturing and packaging services to consumer brands and retailers in the form of flexible stick packs, pouches and other single-use flexible packaging formats.

Food & Drink Business

Pure Wine Co has been appointed as the exclusive national mainland distributor for Tasmanian winery, Pipers Brook Vineyard. Effective from 1 March, Pure Wine Co will manage national mainland distribution and trade sales for Pipers Brook and its Kreglinger Sparkling, Pipers Tasmania and Ninth Island labels.

The fourth round of the federal government’s Traceability Grants Program is now open for applications, with funding from $50,000 to $500,000 available for projects modernising and enhancing agricultural traceability systems.

The rapid rise of GLP-1 weight loss medications is driving profound changes in consumer behaviour overseas – and Australia’s retail sector should prepare now. New data from Circana shows GLP-1 uptake has already reached meaningful scale in Australia, with 12 per cent of households reporting at least one member using a GLP-1 medication, as of September 2025.